M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 8 EUR -1.48% Market Closed
Market Cap: 111.4m EUR

Relative Value

The Relative Value of one MAAT stock under the Base Case scenario is 1.9 EUR. Compared to the current market price of 8 EUR, Maat Pharma SA is Overvalued by 76%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MAAT Relative Value
Base Case
1.9 EUR
Overvaluation 76%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
60
vs Industry
23
Median 3Y
45.9
Median 5Y
44.9
Industry
7.5
Forward
36.7
vs History
vs Industry
Median 3Y
-5.8
Median 5Y
-5.8
Industry
21.4
Forward
-3.6
vs History
vs Industry
Median 3Y
-6.2
Median 5Y
-6.3
Industry
21.1
vs History
vs Industry
Median 3Y
-6.2
Median 5Y
-7.8
Industry
23.5
vs History
15
vs Industry
17
Median 3Y
3.3
Median 5Y
3.3
Industry
2.4
vs History
57
vs Industry
20
Median 3Y
36.8
Median 5Y
36.2
Industry
7.3
Forward
29.4
vs History
57
vs Industry
13
Median 3Y
50.9
Median 5Y
50.8
Industry
8.8
vs History
vs Industry
Median 3Y
-4.2
Median 5Y
-4.4
Industry
4.3
Forward
-3.6
vs History
vs Industry
Median 3Y
-4
Median 5Y
-4.2
Industry
4
Forward
-3.4
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-4.9
Industry
6.1
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-4.7
Industry
4.1
vs History
63
vs Industry
26
Median 3Y
7.7
Median 5Y
7.5
Industry
4.4

Multiples Across Competitors

MAAT Competitors Multiples
Maat Pharma SA Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Maat Pharma SA
PAR:MAAT
111.3m EUR 43.3 -4.6 -3.9 -3.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 563 372.2 -183 286 -222 567.5 -220 027.8
US
Abbvie Inc
NYSE:ABBV
303.2B USD 5.5 59.7 14.9 23
US
Amgen Inc
NASDAQ:AMGN
146.3B USD 4.5 34.6 16.4 31.1
US
Gilead Sciences Inc
NASDAQ:GILD
114.4B USD 4 908.2 10.1 10.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.8B USD 10.2 -226.7 22.4 23.6
US
Epizyme Inc
F:EPE
94.1B EUR 1 826.8 -466.2 -507.7 -494.1
AU
CSL Ltd
ASX:CSL
132.9B AUD 5.6 31.2 19.4 24.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75B USD 5.4 16.1 14.6 16.2
US
Seagen Inc
F:SGT
39.3B EUR 17.6 -54 -57.9 -52.3
NL
argenx SE
XBRU:ARGX
38.1B EUR 17.9 -347.5 -165.2 -107.6
P/S Multiple
Revenue Growth P/S to Growth
FR
M
Maat Pharma SA
PAR:MAAT
Average P/S: 3 505 937.6
43.3
31%
1.4
FR
Pharnext SCA
OTC:PNEXF
38 563 372.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.5
6%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.5
8%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
4
3%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
1 826.8
N/A N/A
AU
CSL Ltd
ASX:CSL
5.6
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.4
7%
0.8
US
S
Seagen Inc
F:SGT
17.6
30%
0.6
NL
argenx SE
XBRU:ARGX
17.9
53%
0.3
P/E Multiple
Earnings Growth PEG
FR
M
Maat Pharma SA
PAR:MAAT
Average P/E: 210
Negative Multiple: -4.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -183 286 N/A N/A
US
Abbvie Inc
NYSE:ABBV
59.7
72%
0.8
US
Amgen Inc
NASDAQ:AMGN
34.6
20%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
908.2
21%
43.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -226.7
14%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -466.2 N/A N/A
AU
CSL Ltd
ASX:CSL
31.2
18%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
13%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -54 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -347.5 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
M
Maat Pharma SA
PAR:MAAT
Average EV/EBITDA: 16.3
Negative Multiple: -3.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -222 567.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.9
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
16.4
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
5%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.4
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.7 N/A N/A
AU
CSL Ltd
ASX:CSL
19.4
12%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.6
10%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -165.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
M
Maat Pharma SA
PAR:MAAT
Average EV/EBIT: 21.4
Negative Multiple: -3.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 027.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
24%
1
US
Amgen Inc
NASDAQ:AMGN
31.1
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.6
13%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -494.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.2
16%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.3 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -107.6 N/A N/A